Photo from wikipedia
Key Points Question Are biosimilars of adalimumab, etanercept, and infliximab associated with equivalent treatment compared with their reference biologic drugs for the management of rheumatoid arthritis? Findings In this systematic… Click to show full abstract
Key Points Question Are biosimilars of adalimumab, etanercept, and infliximab associated with equivalent treatment compared with their reference biologic drugs for the management of rheumatoid arthritis? Findings In this systematic review and meta-analysis of 25 randomized clinical trials that included data on 10 642 patients with rheumatoid arthritis, patients using biosimilars had equivalent clinical responses and functional capacity compared with patients using reference biologic drugs. Meaning These findings suggest that biosimilars may yield therapeutically equivalent outcomes compared with reference biologic drugs for the management of rheumatoid arthritis.
Journal Title: JAMA Network Open
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!